Massivemarkets

EIKN

Eikon Therapeutics, Inc. Common Stock

Nasdaq · usd

$6.22-1.04 (-14.30%)
As of 2:05:20 PM EDT on Oct 26, 2026 · 15-minute delayed

Eikon Therapeutics, Inc. Common Stock (EIKN) trades at $6.22 (-14.30%) as of 2:05:20 PM EDT on Oct 26, 2026, -20.83% over the past month. Market cap is $393.24M, with 8.8 days to cover in short interest.

Stock performance

How Eikon Therapeutics, Inc. Common Stock (EIKN) stock has performed from one day to one year, with its 52-week range.

-11.02%
-$0.77 over 1D
$6.27$6.60$6.93$7.276:00 AM10:30 AM11:45 AM12:55 PM2:05 PM$6.22
1D
-13.64%
1W
-18.57%
1M
-20.83%
YTD
-58.20%
1Y
-58.20%
52-wk range
$6.15 – $17.40

Key statistics

Today's trading snapshot for EIKN: day range, open, previous close, volume and market cap.

Day range
$6.15 – $7.44
Open
$7.20
Prev close
$7.26
Volume
520.66K
Market cap
$393.24M
Shares out
54.17M

8-K filings

Material corporate events Eikon Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Clinical trial resultsOct 23, 2026

    “On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.” The filing reports safety, tolerability, pharmacokinetic, objective response, disease-control, and duration-of-response data from multiple Phase 1/2 clinical trial cohorts.

  • Investor presentationAug 14, 2026

    On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  • Director departureAug 3, 2026

    Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the "Company"). Dr. Chen's and Mr. Wolfe's resignations were not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

  • Director appointmentJun 10, 2026

    On June 5, 2026, the Board of Directors (the "Board") of Eikon Therapeutics, Inc. (the "Company") appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026. Ms. Francisco will initially serve on the Compensation Committee of the Board.

  • Investor presentationJun 1, 2026

    On May 30, 2026, Eikon Therapeutics, Inc. (the 'Company') updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

EIKN short interest

How heavily EIKN is shorted: shares short, days to cover and average daily volume.

Days to cover
8.8
Short interest
6.29M
Avg volume
716.05K

As of · reported to FINRA twice monthly.

EIKN news

The latest news and headlines about Eikon Therapeutics, Inc. Common Stock (EIKN).

Frequently asked questions

What is the Eikon Therapeutics, Inc. Common Stock (EIKN) stock price today?

Eikon Therapeutics, Inc. Common Stock (EIKN) is trading at $6.22 (-14.30% on the day) as of 2:05:20 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Eikon Therapeutics, Inc. Common Stock?

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs.

What is the short interest in EIKN?

As of Sep 30, 2026, EIKN has 6.29M shares short and 8.8 days to cover.

What exchange is EIKN listed on?

Eikon Therapeutics, Inc. Common Stock (EIKN) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of EIKN with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a EIKN analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.